Clinical Trial

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Study acronym: BoneZone
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The Bone Zone trial is a prospective, multi-centre, double-blind, phase II, randomised controlled trial evaluating the effect of denosumab or zoledronic acid compared to placebo on change in bone mineral density over one year in women aged 50 years or older and men aged 70 years or older requiring admission to intensive care for greater than 24 hours. 450 women aged 50 years or older and men aged 70 years or older, admitted to intensive care for greater than 24 hours will be recruited into the study from participating study centres.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2020-10-25; most recent amendment 2026-03-02.
Status change: Not Yet Recruiting → Recruiting 2021-07-14
Trial Details
NCT Number NCT04608630
Lead Sponsor Australian and New Zealand Intensive Care Research Centre
Conditions Critical Illness, Osteoporosis
Enrollment 450 participants
Start Date 2021-07-15
Primary Completion 2027-02-28 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-04